Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.12 HKD | +4.55% | +17.95% | +5.24% |
15/04 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
15/04 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
Evolution of the average Target Price on Ocumension Therapeutics
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Ocumension Therapeutics
UBS |
EPS Revisions
- Stock Market
- Equities
- 1477 Stock
- Consensus Ocumension Therapeutics